Barr to market generic LAMISIL tablets

Editorial Checklist Reviewed
Jul 4 2007NewsGuard 100/100 Score

Barr Pharmaceuticals has announced that Gedeon Richter, Plc. has received final U.S. Food & Drug Administration (FDA) approval for its application to manufacture and market a generic version of Novartis Pharmaceutical Corporation's LAMISIL (terbinafine hydrochloride) Tablets, 250 mg. The approval follows the expiration of pediatric exclusivity for LAMISIL.

Under the terms of an agreement with Gedeon Richter, Gedeon Richter will manufacture the product and Barr will market the product in the United States and pay Gedeon Richter a royalty. Barr plans to launch the product immediately.

LAMISIL had annual sales of approximately $685 million for the twelve months ended April 2007, based on IMS sales data.

Terbinafine hydrochloride tablets are indicated for the treatment of onychomycosis of the toenail or fingernail due to dermatophytes.

Source:

http://www.barrlabs.com/

Posted in: Pharmaceutical News

Tags: , , , ,

Comments (0)

Suggested Reading

Living in food deserts during early childhood raises long-term obesity risk
Social media normalizes unhealthy food choices, shaping youth habits and brand loyalty
Ultra-processed foods dominate children's diets from toddlerhood to middle childhood
Key triggers for food allergies in children after organ transplants
Updated Food Compass 2.0 improves food health ratings using new diet data
Ultra-processed food linked to weight gain and lower well-being in adolescents
Six common flying with food allergies myths
Limiting fast-food outlets can reduce childhood overweight and obesity

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Study finds thousands of food-contact chemicals in humans, raising safety concerns